Sefaxersen sodium
As of the edition of 20 October 2026, Sefaxersen sodium is an oligonucleotide: stopped in 2018; acts on CFB.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2018
- Kind
- Oligonucleotide
- Registered trials
- 3, 1 stopped early
- Disease areas
- Eye; Immune system; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CFB | Complement factor B | P00751 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 3 | 2 | 0 | 1 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Akcea Therapeutics | Lead sponsor of trials | 2018 to now |